NCT07573397Not yet recruiting
A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have higher pCR. The main question it aims to answer is: Whether precursor exhausted T cells (Tpex) in negative tumor-draining lymph nodes have better predictive efficacy for treatment response than PD-L1 CPS.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 88 (estimated)
- First submitted
- 1 May 2026
- Start date
- 6 May 2026
- Primary completion date
- 1 May 2028
- Lead sponsor
- Fudan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07573397
What you commit to
- Study type: Observational
- Planned participants: 88
- From 6 May 2026 to the primary completion date, 1 May 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Esophageal perforation or hematemesis
- Any active autoimmune disease or a history of autoimmune disease
- Disease progression occurs within 3months after PD-1 immunotherapy.
- Allergic to macromolecular protein preparations, or to any of the ingredients in PD-1 inhibitors for injection.
- Uncontrolled heart diseases or clinical symptoms
- Congenital or acquired immunodeficiency (such as HIV infection); active hepatitis B (HBV-DNA≥104 copy number/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the detection limit of the analytical method); active tuberculosis.
Who the study is looking for
- Histologically confirmed esophageal squamous cell carcinoma
- patients eligible for surgery
- plan to treated with neoadjuvant PD-1 immunotherapy
- Eastern Cooperative Oncology Group(ECOG) performance status: 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.